background
object
bronchiectasi
grow
health
burden
global
australasia
associ
repeat
respiratori
infect
diseas
often
result
hospit
admiss
impair
qualiti
life
reduc
lung
function
shorten
life
expect
describ
local
clinic
physiolog
sputum
characterist
patient
hospit
infect
exacerb
bronchiectasi
method
studi
examin
medic
record
adult
admit
metropolitan
australian
hospit
infect
exacerb
bronchiectasi
calendar
year
result
baselin
characterist
includ
mean
sd
age
particip
year
women
current
exsmok
major
coexist
medic
condit
asthma
copd
asthma
copd
seventytwo
percent
regular
inhal
medic
cyclic
antibiot
undertook
regular
respiratori
physiotherapi
bronchodil
revers
present
small
airway
revers
sputum
demonstr
normal
flora
pseudomona
aeruginosa
haemophilu
influenza
organ
mean
number
exacerb
per
year
requir
hospit
sixtytwo
percent
subject
index
rel
socioeconom
disadvantag
decil
risk
factor
exacerb
includ
histori
asthma
copd
document
small
airway
revers
presenc
p
aeruginosa
conclus
patient
hospit
infect
exacerb
bronchiectasi
predominantli
older
comorbid
lower
socioeconom
statu
presenc
p
aeruginosa
risk
factor
repeat
exacerb
histori
asthma
copd
small
airway
revers
addit
pathogen
microorgan
especi
pseudomona
aeruginosa
frequent
exacerb
requir
hospit
bronchiectasi
associ
comorbid
asthma
copd
bronchodil
revers
patient
often
lower
socioeconom
background
respirolog
v
ven
et
al
asian
pacif
societi
respirolog
respirolog
v
ven
et
al
bronchiectasi
signific
grow
health
burden
global
australasia
clinic
cours
cystic
fibrosi
cf
bronchiectasi
wide
studi
howev
less
known
regard
noncf
bronchiectasi
clinic
character
symptom
product
cough
recurr
chest
infect
patholog
radiolog
inflam
dilat
airway
bronchiectasi
often
result
prolong
hospit
admiss
frequent
antibiot
treatment
impair
qualiti
life
reduc
lung
function
repeat
exacerb
specif
three
year
associ
higher
mortal
follow
year
popul
identifi
greatest
risk
develop
bronchiectasi
includ
indigen
group
socioeconom
depriv
person
individu
suffer
comorbid
individu
moder
forc
expiratori
volum
fev
sever
fev
copd
patient
often
increas
rate
bronchial
infect
increas
mortal
reduc
lung
function
alon
independ
smoke
histori
also
associ
increas
mortal
bronchiectasi
well
document
literatur
copdrel
bronchiectasi
associ
sever
diseas
rheumatoid
arthritisrel
diseas
recent
exist
asthma
associ
independ
increas
risk
bronchiectasi
exacerb
characterist
sputum
colon
chronic
infect
bronchiectasi
exacerb
grow
area
interest
two
common
pathogen
isol
pseudomona
aeruginosa
haemophilu
influenza
chronic
infect
p
aeruginosa
associ
threefold
increas
risk
death
higher
rate
hospit
admiss
greater
exacerb
lower
fev
compar
h
influenza
sinc
widespread
use
comput
tomographi
ct
identif
diagnosi
bronchiectasi
increas
global
interest
phenotyp
patient
bronchiectasi
aim
studi
describ
clinic
physiolog
sputum
characterist
australian
group
patient
hospit
metropolitan
healthcar
provid
infect
exacerb
bronchiectasi
western
health
wh
serv
peopl
western
suburb
melbourn
commun
serv
wh
draw
divers
cultur
linguist
background
socioeconom
disadvantag
exist
great
part
region
medic
record
adult
patient
n
acut
exacerb
bronchiectasi
admit
calendar
year
examin
electron
hospit
note
clinic
code
bronchiectasi
posit
ct
diagnosi
bronchiectasi
includ
n
patient
inform
retrospect
gather
electron
written
inpati
outpati
note
laboratori
result
discharg
summari
radiolog
imag
report
bronchiectasi
diagnos
accord
standard
guidelin
name
presenc
symptom
posit
ct
chest
scan
patient
demograph
collect
includ
postcod
assess
socioeconom
statu
socioeconom
index
area
seifa
index
rel
socioeconom
disadvantag
irsd
irsd
categor
socioeconom
statu
base
postcod
use
decil
lowest
decil
repres
disadvantag
higher
decil
repres
least
disadvantag
exacerb
defin
admiss
hospit
increas
one
follow
cough
sputum
dyspnoea
andor
wheez
exacerb
manag
commun
includ
respiratori
symptom
includ
haemoptysi
associ
comorbid
document
directli
patient
record
asthma
document
patient
histori
copd
document
patient
histori
spirometri
evid
persist
airflow
limit
examin
find
laboratori
test
record
particular
includ
routin
sputum
microscopi
cultur
sensit
mc
lung
function
test
name
fev
forc
expiratori
flow
fef
forc
vital
capac
reflect
small
medium
airway
function
respons
bronchodil
undertaken
period
patient
stabil
prior
exacerb
presenc
bronchodil
revers
defin
american
thorac
societi
at
criteria
ml
improv
postbronchodil
fev
baselin
spirometri
small
medium
airway
fef
revers
document
use
abovedescrib
criteria
bronchiectasi
sever
use
valid
composit
multidimension
score
face
fev
age
chronic
colon
extens
dyspnoea
score
predictor
mortal
calcul
inpati
treatment
outpati
treatment
record
number
exacerb
one
calendar
year
calcul
studi
receiv
approv
region
ethic
descript
statist
use
summar
clinic
characterist
particip
normal
outcom
data
test
data
record
count
percentag
correl
calcul
pearson
spearman
correl
coeffici
depend
normal
data
gener
linear
model
analys
use
determin
variabl
independ
associ
exacerb
name
histori
asthma
histori
copd
presenc
p
aeruginosa
fev
fef
revers
poisson
regress
model
analysi
undertaken
exacerb
frequenc
binari
logist
regress
analysi
undertaken
two
exacerb
depend
variabl
signific
note
p
data
analysi
perform
use
spss
version
statist
softwar
ibm
usa
clinic
code
identifi
patient
diagnosi
bronchiectasi
four
exclud
neg
normal
ct
result
sixtyon
set
patient
note
examin
total
admiss
baselin
patient
characterist
describ
tabl
mean
sd
age
particip
year
includ
femal
subject
nonsmok
current
exsmok
packyear
avail
previou
current
smoker
mean
sd
packyear
histori
coexist
medic
condit
describ
tabl
histori
asthma
note
copd
seventytwo
percent
patient
regular
inhal
cyclic
antibiot
undertook
regular
respiratori
physiotherapi
moder
airflow
obstruct
note
lung
function
test
mean
fev
l
predict
bronchodil
revers
larg
airway
fev
present
subject
record
spirometri
n
posit
mannitol
test
airway
hyperrespons
present
one
patient
without
bronchodil
revers
thu
patient
support
spirometri
evid
asthma
medium
small
airway
revers
document
mean
sd
revers
bronchiectasi
sever
classif
use
face
score
avail
patient
categor
moder
sever
diseas
studi
find
describ
tabl
normal
flora
present
case
p
aeruginosa
h
influenza
organ
mean
sd
exacerb
rate
per
year
previou
exacerb
five
exacerb
previou
year
sixtysix
percent
n
patient
one
exacerb
one
year
p
aeruginosa
exacerb
antibiot
resist
defin
routin
cultur
sensit
part
mc
correct
ad
march
first
onlin
public
two
exacerb
one
calendar
year
amend
one
exacerb
one
year
major
patient
irsd
record
lowest
decil
individu
amongst
disadvantag
decil
grew
p
aeruginosa
subject
irsd
record
lowest
decil
individu
lower
socioeconom
area
experienc
increas
rate
exacerb
experienc
three
exacerb
year
record
lowest
irsd
decil
decil
signific
correl
note
age
correl
coeffici
r
p
symptom
sputum
product
r
p
histori
asthma
r
p
histori
copd
r
p
fev
p
p
fef
revers
r
p
presenc
organ
sputum
r
p
presenc
p
aeruginosa
sputum
r
p
signific
predictor
exacerb
frequenc
includ
asthma
regress
coeffici
p
copd
p
p
aeruginosa
p
fev
p
fef
revers
p
signific
risk
associ
note
two
exacerb
fef
bronchodil
revers
p
fev
revers
adult
patient
hospit
infect
exacerb
bronchiectasi
seri
predominantli
older
comorbid
lower
socioeconom
statu
antibioticrespons
p
aeruginosa
valu
mean
sd
percentag
absolut
number
base
imput
data
face
score
face
fev
age
chronic
colon
extens
dyspnoea
fev
forc
expiratori
volum
irsd
index
rel
socioeconom
disadvantag
sd
standard
deviat
correct
ad
march
first
onlin
public
three
type
exacerb
outcom
tabl
remov
request
author
characterist
similar
observ
clinic
stabl
patient
bronchiectasi
current
studi
cultur
p
aeruginosa
popul
respons
antibiot
wherea
cultur
p
aeruginosa
antibiot
resist
similar
studi
p
aeruginosa
cultur
associ
increas
exacerb
frequenc
h
influenza
associ
lower
exacerb
frequenc
exacerb
frequenc
time
greater
presenc
h
influenza
p
aeruginosa
isol
togeth
tabl
compar
h
influenza
alon
novel
find
accord
knowledg
less
frequent
isol
includ
aspergillu
mycobacterium
legionella
achromobact
viral
influenza
gao
et
al
found
preval
viral
infect
name
rhinoviru
coronaviru
influenza
detect
pcr
higher
individu
bronchiectasi
exacerb
clinic
stablil
presenc
substanti
bacteri
viral
popul
bronchial
tree
clinic
concern
howev
given
small
number
isol
p
aeruginosa
h
influenza
analysi
regard
influenc
microbiota
target
antibiot
use
beyond
scope
studi
coexist
copd
bronchiectasi
associ
poorer
outcom
well
establish
approxim
half
exacerb
occur
patient
copd
bronchiectasi
occur
patient
histori
asthma
evid
airway
reactiv
lung
function
test
patient
histori
asthma
time
increas
risk
experienc
exacerb
compar
individu
without
histori
asthma
recent
literatur
suggest
asthma
coexist
bronchiectasi
associ
frequent
exacerb
compar
bronchiectasi
alon
mao
et
al
found
patient
bronchiectasi
asthma
time
increas
risk
experienc
exacerb
without
associ
asthma
thirtyon
percent
patient
bronchiectasi
histori
asthma
copd
recent
literatur
report
increas
preval
bronchiectasi
patient
asthma
copd
overlap
syndrom
aco
compar
asthma
copd
alon
effect
coexist
aco
bronchiectasi
term
diseas
progress
exacerb
frequenc
unknown
requir
investig
small
airway
inflamm
reactiv
increas
import
bronchiectasi
studi
demonstr
measur
small
airway
function
forc
midexpiratori
flow
fef
may
reflect
mucu
plug
sputum
clearanc
improv
fef
note
mucolyt
treatment
copd
signific
associ
note
fef
revers
exacerb
frequenc
chang
fef
revers
associ
increas
risk
two
exacerb
definit
signific
revers
measur
remain
broad
underresearch
debat
often
rang
studi
chose
priori
standard
definit
use
determin
signific
revers
larg
small
airway
function
result
need
interpret
caution
given
known
variabl
fef
associ
signal
warrant
research
larger
patient
number
prospect
trial
given
rapidli
grow
bodi
evid
within
literatur
older
age
sputum
product
presenc
poorer
lung
function
measur
fev
presenc
p
aeruginosa
sputum
factor
known
associ
exacerb
confirm
studi
report
greater
rate
readmiss
other
recent
publish
robert
et
al
report
readmiss
rate
within
period
author
found
signific
associ
ethnic
origin
depriv
score
similarli
current
studi
found
patient
admit
infect
exacerb
deem
lowest
five
decil
term
disadvantag
given
larg
percentag
subject
low
socioeconom
decil
unabl
determin
signific
p
aeruginosa
cultur
socioeconom
statu
patient
undergo
regular
physiotherapi
surpris
find
given
current
guidelin
treatment
noncf
bronchiectasi
recommend
routin
respiratori
physiotherapi
recent
metaanalysi
found
patient
undergo
regular
exercis
train
fewer
exacerb
month
patient
undergo
supervis
outpati
exercis
pulmonari
rehabilit
programm
experienc
shortterm
improv
exercis
capac
healthrel
qualiti
life
research
examin
clinic
benefit
airway
clearanc
techniqu
bronchiectasi
spars
adher
respiratori
physiotherapi
airway
clearanc
techniqu
low
bronchiectasi
mccullough
et
al
demonstr
random
control
trial
prospect
studi
phenotyp
bronchiectasi
exacerb
particip
bronchiectasi
maintain
regular
airway
clearanc
techniqu
end
year
regular
airway
clearanc
howev
associ
improv
within
treatment
burden
respiratori
symptom
domain
qualiti
life
bronchiectasi
questionnair
thu
lower
rate
adher
unexpect
real
life
studi
furthermor
associ
socioeconom
statu
educ
access
adher
regular
physiotherapi
subsequ
exacerb
determin
limit
studi
includ
retrospect
design
small
sampl
size
well
accuraci
diagnos
asthma
copd
obtain
admiss
asthma
normal
defin
presenc
episod
symptom
breathless
wheez
cough
chest
tight
support
evid
revers
either
spirometri
test
airway
hyperrespons
asthma
defin
histor
studi
spirometr
criteria
appli
similarli
copd
defin
patient
histori
evid
persist
airflow
limit
spirometri
nine
patient
copd
classifi
nonsmok
patient
includ
analysi
smoke
remain
predomin
caus
copd
exposur
environment
pollut
includ
passiv
smoke
genet
caus
alpha
antitrypsin
defici
could
exclud
furthermor
variabl
smoke
histori
nonsmok
indic
current
statu
rather
neversmok
statu
combin
lack
packyear
data
signific
proport
patient
reflect
limit
patient
admiss
record
yet
provid
snapshot
hospit
patient
studi
character
patient
admit
hospit
infect
exacerb
bronchiectasi
confirm
lower
socioeconom
statu
comorbid
asthma
copd
growth
potenti
pathogen
microorgan
ppm
sputum
associ
increas
rate
exacerb
confirm
burden
care
bronchiectasi
high
australian
set
subject
current
studi
readmit
least
one
exacerb
within
period
manag
target
socioeconom
factor
optim
coexist
morbid
well
erad
ppm
sputum
clearanc
techniqu
respiratori
physiotherapi
appropri
antibiot
therapi
research
studi
previous
present
european
respiratori
societi
congress
